🇺🇸 metoprolol/HCT in United States
13 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 13
Most-reported reactions
- Dyspnoea — 3 reports (23.08%)
- Nausea — 2 reports (15.38%)
- Abdominal Discomfort — 1 report (7.69%)
- Blood Pressure Inadequately Controlled — 1 report (7.69%)
- Blood Urine Present — 1 report (7.69%)
- Burning Sensation — 1 report (7.69%)
- Cardiac Failure Congestive — 1 report (7.69%)
- Chest Discomfort — 1 report (7.69%)
- Confusional State — 1 report (7.69%)
- Diarrhoea — 1 report (7.69%)
Other Cardiovascular approved in United States
Frequently asked questions
Is metoprolol/HCT approved in United States?
metoprolol/HCT does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for metoprolol/HCT in United States?
Abbott is the originator. The local marketing authorisation holder may differ — check the official source linked above.